Corcept Therapeutics Inc.
149 Commonwealth Drive
Menlo Park,
CA 94025
United States - Map
Phone: 650-327-3270
Fax: 650-327-3218
Web Site: http://www.corcept.com
| Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the development of drugs for the treatment of severe metabolic and psychiatric disorders. The company focuses on the development of drugs for disorders that are associated with irregular levels of the steroid hormone called cortisol. Its lead product is CORLUX, a glucocorticoid receptor II (GR-II) antagonist, which is in Phase III clinical trials for the treatment of Cushing's Syndrome and for psychotic depression. The company is also developing next-generation selective GR-II antagonists for other major metabolic and psychiatric disorders. It has exclusive patent license from Stanford University for the use of GR-II antagonists, as well as has agreements with ICON Clinical Research, LP; and MedAvante, Inc. The company was founded in 1998 and is headquartered in Menlo Park, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Joseph K. Belanoff M.D., 51
Co-Founder, Chief Exec. Officer |
N/A
| N/A | Dr. Robert L. Roe M.D., F.A.C.P, 67
Pres and Sec. |
N/A
| N/A | Ms. Caroline M. Loewy , 42
Chief Financial Officer |
$
25.00K | N/A | Ms. Anne M. LeDoux , 61
Chief Accounting Officer, VP and Controller |
$
228.00K | N/A | Dr. Alan F. Schatzberg M.D., 64
Co-Founder |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.03% Nasdaq 
0.07 (3.04%) 
Profile
